Late infantile neuronal ceroid lipofuscinosis (LINCL) is an autosomal recessive neurodegenerative disease caused by mutations in CLN2, which encodes the lysosomal protease tripeptidyl peptidase 1 (TPP1). LINCL is characterized clinically by progressive motor and cognitive decline, and premature death. Enzyme-replacement therapy (ERT) is currently available for lysosomal storage diseases affecting peripheral tissues, but has not been used in patients with central nervous system (CNS) involvement. Enzyme delivery through the cerebrospinal fluid is a potential alternative route to the CNS, but has not been studied for LINCL. In this study, we identified relevant neuropathological and behavioral hallmarks of disease in a mouse model of LINCL and correlated those findings with tissues from LINCL patients. Subsequently, we tested if intraventricular delivery of TPP1 to the LINCL mouse was efficacious. We found that infusion of recombinant human TPP1 through an intraventricular cannula led to enzyme distribution in several regions of the brain of treated mice. In vitro activity assays confirm increased TPP1 activity throughout the rostral-caudal extent of the brain. Importantly, treated mice showed attenuated neuropathology, and decreased resting tremor relative to vehicle-treated mice. This data demonstrates that intraventricular enzyme delivery to the CNS is feasible and may be of therapeutic value.
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IntroductIon
Late infantile neuronal ceroid lipofuscinosis (LINCL) is one of numerous autosomal recessive neurodegenerative diseases caused by lysosomal protein mutations and characterized clinically by progressive motor and cognitive decline, vision loss, seizures, and premature death. 1 These disorders are categorized as lysosomal storage diseases based on their characteristic intracellular protein aggregates, and as a group, have a collective world-wide incidence of ~1 in 12,500 (ref. 2) . Currently available treatments for these disorders are merely supportive and do not alter disease progression, supporting investigations into novel treatment approaches.
LINCL is caused by mutations in the CLN2 gene (chromosome 11p15, MIM#204500), which encodes the lysosomal protease tripeptidyl peptidase 1 (TPP1). 3 The lack of TPP1 activity results in central nervous system (CNS) degeneration. [4] [5] [6] A mouse model of LINCL has been generated by targeting CLN2, resulting in undetectable levels of TPP1, and the recapitulation of many characteristics of the human disease including motor dysfunction, CNS pathology, and reduced lifespan. 7 In this work, we present additional characterization of neuropathology and behavior in the TPP1-deficient mouse, as well as neuropathology in human LINCL tissues.
Gene transfer studies in TPP1-deficient mice suggest that restoration of enzyme activity can improve the disease phenotype. [8] [9] [10] While some may consider gene transfer as the ultimate cure for treating recessive genetic disorders such as lysosomal storage diseases, enzyme replacement therapy (ERT) has already shown clinical benefit for some of these diseases, such as non-neuronopathic Gaucher disease, Fabry disease, Pompe disease, and several of the mucopolysaccharidoses. [11] [12] [13] [14] [15] [16] Of note, intravenous ERT has thus far been effective only for those storage diseases that affect primarily peripheral tissues, and has not been effective for CNS disease in patients due to inefficient passage of enzymes across the bloodbrain barrier. Thus, intravenous administration of recombinant TPP1 is unlikely to have any therapeutic value for CNS disease in LINCL. Although it is possible to permeabilize the blood-brain barrier with osmotic or other agents experimentally, [17] [18] [19] this is not a viable option in a clinical setting where repeated enzyme administration may be necessary.
An alternative delivery strategy is to bypass the blood-brain barrier completely with direct injections to the brain parenchyma or ventricular space. Studies in nonhuman primates demonstrate the feasibility of glucocerebrosidase delivery directly into the brain, and that enzyme spread can be further enhanced via www.moleculartherapy.org vol. 16 no. 4 april 2008 a technique termed 'convection-enhanced delivery' . 20 However, the invasiveness of intraparenchymal injections is a major limitation in a clinical setting. Intrathecal enzyme delivery is also feasible, and potentially much less invasive than intraparenchymal injection. 21 Intrathecal delivery takes advantage of the large surface area of the brain that comes in contact with cerebrospinal fluid, either through ependyma-lined ventricular surfaces, or perivascular (Virchow-Robbins) spaces. In the canine model of mucopolysaccharidosis type I, intrathecal injection of human α-l-iduronidase led to reductions in brain and meningeal glycosaminoglycan levels, as well as histological improvements in lysosomal storage, 21 suggesting that exogenous enzymes can be endocytosed and trafficked correctly to lysosomes. In this study, we tested the therapeutic efficacy of intraventricular TPP1 infusion in the TPP1-deficient mouse, and demonstrated that several behavioral and neuropathological phenotypes in this mouse are attenuated following enzyme delivery. results neuropathology of tPP1-deficient mouse and lIncl patient tissue The TPP1-deficient mouse has been previously reported to exhibit widespread neuropathology. 7 Although sparce loss of cerebellar Purkinje cells was originally reported, it was surprising that overt neuron loss within the CNS was not observed given the pronounced motor deficits in this mouse, and the extent of neurodegeneration in LINCL patients. Here we present more detailed characterization and quantitation of neuropathology in the TPP1-deficient mouse, including the identification of several degenerating neuronal populations that may be significant in the disease progression in this mouse, and of relevance to LINCL patients.
Reactive astrocytosis is a well-described pathological process that generally occurs in response to neuron injury or dysfunction in the CNS. To determine the extent of astrocytosis in the TPP1-deficient mouse CNS, we immunostained brain sections from mice of various ages for glial fibrillary acidic protein (GFAP). TPP1-deficient mice exhibit progressive reactive astrocytosis in several regions of the brain, including the motor cortex, hippocampus, striatum, and cerebellum (Figure 1a-f) , in contrast to heterozygous control mice which show little to no astrocytosis. Thresholding analysis with the public domain software Image J 22 was used to determine the relative extent of GFAP immunoreactivity. This analysis revealed a significant degree of astrocytosis in the primary motor cortex as early as at 63 days of age, which progresses aggressively to include most CNS structures by 99 days of age, and continues to intensify until the end stage of disease at 148 days of age (Figure 1g) .
Reactive astrocytosis is observed in the cerebellum of TPP1-deficient mice but not in the heterozygous controls (Figure 2a  and b) . Severe astrocytosis occurs in the granule cell layer and appears to be homogeneous throughout this layer, whereas the molecular layer exhibits sporadic patches of gliosis corresponding to reactive Bergmann glia. No apparent pattern was observed as to which lobules of the cerebellum were more susceptible to this event, but interestingly, the patches of Bergmann gliosis occur in regions where Purkinje cells are lost, as demonstrated by co-immunostaining for GFAP and the Purkinje cell marker calbindin (Figure 2c and d) .
Cerebellar neuron loss in TPP1-deficient mice is not confined to Purkinje cells. Neurons of the deep cerebellar nuclei (DCNs), as visualized by Nissl stain or Neu-N immunostaining, also degenerate in these mice, which exhibit a near complete loss of DCN neurons by 150 days of age, whereas those of heterozygote mice remain intact (Figure 2e and f) . Neurons in the lateral medullary reticular formation are also lost in the TPP1-deficient mouse but remain intact in heterozygous controls (Figure 2g and h) .
Tissue specimens from LINCL patient brains exhibit pathological findings similar to those noted in TPP1-deficient mice. Sections through the primary motor cortex show fewer neurons and a prominent astroglial response (Figure 3a and b) . In some cases, the hypertrophied astrocytes encircle the remaining cortical neurons. Clusters of what appear to be microglia are also evident (Figure 3b) . In human LINCL cerebellum, the molecular layer is atrophic with pronounced granule neuron loss and an almost complete absence of Purkinje cells (Figure 3c and d) . As with neurons in the cortex, the few Purkinje cells remaining in the LINCL cerebellum are distended with cytoplasmic storage 
Intraventricular enzyme delivery
Several studies suggest that the cerebrospinal fluid can mediate the distribution of lysosomal enzymes and their subsequent uptake into the brain parenchyma. 21, 23 To test if TPP1 can be delivered in this manner, we infused recombinant human TPP1 proenzyme (1 mg/ml) directly into the lateral ventricles of TPP1-deficient mice. Osmotic pumps each delivered 100 µl enzyme through a cannula implanted in the right lateral ventricle. Correct cannula placement was confirmed visually in serial coronal brain sections (Figure 4a) . Delivery of TPP1 in this manner results in enzyme spread to regions of the brain in both hemispheres, particularly the meninges, corpus callosum, and periventricular areas of the cortex and hippocampus (Figure 4b-d) . Interestingly, TPP1 shows a strong propensity to traffic along the corpus callosum (Figure 4c) . Western blots for TPP1 from these brain homogenates show an accumulation of the mature TPP1 enzyme (Figure 4e) , indicating correct trafficking of the proenzyme to the lysosome and appropriate processing to the mature enzyme. In vitro fluorometric TPP1 activity assays with brain homogenate from serial bilateral coronal sections show that ERT-treated mice exhibit elevated TPP1 activity levels which, in all cases, exceeded that of heterozygous mice (Figure 4f) .
effects of enzyme replacement on tremor phenotype
We have shown that intraventricular infusion of recombinant TPP1 can lead to broad distribution of the enzyme in the brain, and appropriate trafficking of the enzyme to the lysosome within the cells of the CNS. We next tested if intraventricular ERT has an effect on the gross motor deficits of TPP1-deficient mice, which have previously been characterized via accelerating and rocking rotarod. 7 The accelerating rotorod, however, does not detect a significant difference in performance until 16 weeks of age, near the end stage of disease in the mouse. Here we developed a behavioral assay to quantify the tremor that is readily observable by eye in the diseased mouse. In this assay, the mouse is placed on a platform, which is attached to a force transducer that continuously detects tremor amplitudes during the testing period.
We initiated enzyme delivery at 60 days of age and assayed for mean tremor amplitude in treated and control mice every 5 days until 105 days of age. At 60 days of age, no statistical difference was detected between CLN2 +/-control mice, CLN2 -/-mice mock-treated with saline, and CLN2 -/-mice treated with ERT. However, by 80 days of age the tremor amplitude of CLN2 +/-control mice decreased, presumably due to habituation to the testing chamber. Both treated and mock-treated mice maintained their starting tremor amplitude until 90 days of age. Between 95 and 105 days of age, however, the tremor amplitude of mock-treated mice increased progressively, whereas that of ERT-treated mice never increased beyond the levels detected at 80 days (Figure 5a) . The mean tremor amplitude of enzyme-treated mice were significantly lower than that of mock-treated mice at 100 and 105 days of age (Figure 5a , P < 0.05).
effect of enzyme replacement on neuropathology
Enzyme-treated TPP1-deficient mice also showed improvements in neuropathological measures. To determine the effect of enzyme delivery on the reactive gliosis observed in the CLN2 -/-mouse, we immunostained for GFAP in brain sections from CLN2 +/-, CLN2 -/-mock-treated, and CLN2 -/-ERT-treated mice. Staining in the primary motor cortex was markedly decreased in ERTtreated mice compared to mock-treated mice (Figure 5b-d) . Thresholding analysis confirms a significant difference exists between ERT and mock-treated groups (Figure 5e , P < 0.005). A similar analysis for autofluorescent storage indicates a significant decrease in autofluorescence in the primary motor cortex of enzyme-treated mice (Figure 5f , P < 0.005). The DCNs of CLN2 +/-mice contain large neurons that stain robustly for Neu-N (Figure 6a) . Analysis of sections from treated and mock-treated LINCL mice revealed that enzyme-treated mice consistently maintained some integrity of the DCNs (Figure 6b ) whereas some mock-treated mice exhibited total loss of Neu-N positive cells (Figure 6c) . To quantify this phenotype, blinded grading of cerebellar sections immunostained for the neuronal marker Neu-N was done by a neuropathologist. For this, a scale of 1-3 was devised where 1 shows few remaining intact neurons; 2 shows intermediate degree of neuron loss; 3 shows no discernable neuron loss. As expected, all heterozygous mice received a grade of 3. Mock-treated mice, however, received grades of 2 and 1.
Importantly, ERT-treated LINCL mice consistently received an intermediate score of 2. dIscussIon Neuropathology: Although TPP1-deficient mice exhibit severe tremor and ataxia, and CNS pathology, 7 the precise time course of neurodegenerative and reactive changes has not previously been defined. In this study, we establish a time course over which reactive gliosis occurs, and identify several neuron populations that degenerate in this mouse model. Reactive gliosis is first observed in the primary motor cortex at 63 days of age, ~1-2 weeks prior to onset of the tremor phenotype. This timing suggests that cortical dysfunction may contribute to the motor deficits observed in this mouse. In addition, neurons of the DCNs and regions of the brainstem reticular formation degenerate almost entirely in the TPP1-deficient mouse. These neurons mediate a variety of physiological functions ranging from motor coordination to respiration, (C-D) ; for panels e-h is 10 µm; for panels k-l 100 µm.
and therefore degeneration of these neuron populations may contribute to the motor deficits displayed by this mouse, and perhaps ultimately its death. Severe Purkinje cell degeneration occurs in LINCL, and was expected to occur in the TPP1-deficient mouse, especially in light of its ataxic phenotype. 7 However, we found that only small patches of Purkinje cells are lost. Initially these appear to be randomly disbursed patches, but our observations suggest that areas of Purkinje cell loss are co-localized with discrete areas of Bergmann gliosis. The precise relationship between these events is currently unclear, but an early activation of astrocytes prior to the onset of neuron loss is a consistent feature of multiple forms of NCL. [24] [25] [26] We show that glial cells accumulate lysosomal storage material like other cells, so it is conceivable that Purkinje cell degeneration may be a secondary result of Bergmann glial dysfunction.
LINCL patient brain tissues exhibit extensive autofluorescent storage and reactive gliosis in the motor cortex and cerebellum, similar to our observations in TPP1-deficient mice. However, cellular degeneration was pronounced in human LINCL tissue, with profound loss of neurons in the motor cortex, cerebellar atrophy, and a dramatic loss of cerebellar Purkinje cells. Consistent with findings in other forms of NCL, 27 the few persisting cortical neurons were frequently encircled by GFAP-positive processes, a characteristic appearance not seen in other lysosomal storage disorders. Within the human LINCL cerebellum, there was also marked astrogliosis. This was accompanied by Bergmann gliosis that involved the entire molecular layer rather than the discrete patches seen in TPP1-deficient mice. As expected, neuronal degeneration in human LINCL cerebellum was accompanied by loss of axons in cerebellar white matter tracts. Although it is unclear why severe cell loss was not observed in the TPP1-deficient mouse, the extensive autofluorescence and reactive gliosis observed in both mouse and human LINCL tissues suggest those may be relevant neuropathological features to monitor in a preclinical study.
Enzyme replacement: Patients afflicted with LINCL suffer and ultimately succumb to symptoms related to CNS dysfunction. 1 As such, it is reasonable to postulate that effective therapies for LINCL will require CNS targeting. Furthermore, the neurological deficits do not appear to be localized to a particular CNS structure, region, or system, [4] [5] [6] suggesting that a large percentage of the CNS volume must be treated. We tested the hypothesis that the cerebrospinal fluid can be exploited to distribute the recombinant TPP1 enzyme globally within the brain. Most lysosomal hydrolases, including TPP1, are known to acquire mannose-6-phosphate residues as they traffic through the golgi apparatus after translation. This post-translational modification mediates the direct intracellular targeting of lysosomal proteins to the lysosome, but importantly, also allows mannose-6-phosphate-mediated endocytosis and lysosomal targeting of extracellular proteins. The purified recombinant TPP1 proenzyme used in our studies contains mannose-6-phosphate and can be readily endocytosed by cultured cells. 28 Importantly, TPP1 proenzyme is known to be extremely stable, and once endocytosed, still has an half-life of 11-12 days. 28 After TPP1 infusion into the lateral ventricle, immunostaining for TPP1 in brain sections shows bilateral enzyme distribution to widespread regions of the brain. In vitro TPP1 activity assays show that TPP1 activity in treated mice ranged from 2-fold to 18-fold that of heterozygous mice throughout the entire rostral-caudal extent of the brain, which is comparable to results obtained from similar studies performed in a canine model of mucopolysaccharidose I. 21 Importantly, heterozygous enzyme activity levels are sufficient to prevent disease, and LINCL leukocytes and fibroblasts typically exhibit undetectable levels of TPP1 activity. 29 Western blots of brain homogenate from enzyme-treated mice show an accumulation of the mature TPP1, indicating that the proenzyme was appropriately trafficked to, and processed in, the lysosomal compartment.
Intravenous ERT has proven to be beneficial for numerous lysosomal storage disorders that affect primarily peripheral tissues, [11] [12] [13] [14] [15] [16] indicating that exogenous enzymes can be functional upon uptake and sorting to the lysosome. We first demonstrated that recombinant TPP1 can be taken up into the brain parenchyma from the cerebrospinal fluid. We next tested the effects of intraventricular ERT on the behavioral and neuropathological phenotypes in the TPP1-deficient mouse. Although both treated and mock-treated mice had tremor amplitudes greater than that of heterozygous controls, ERT-treated mice exhibited attenuated tremor amplitudes relative to mock-treated mice, suggesting that TPP1 replacement may be slowing disease progression. Enzyme-treated mice also showed improvements in neuropathological findings, including decreased gliosis in the motor cortex, decreased autofluorescence, and a partial rescue of the DCNs. These findings are consistent with that of previous enzyme replacement studies in that the exogenous enzyme can be functionally utilized by diseased cells. In this study, TPP1 delivery was confined to a 2-week period due to limitations of the pump used. Nevertheless, the significant phenotypic improvements after such a short duration of enzyme replacement provide encouragement that this approach may be more efficacious if the enzyme delivery can be maintained or readministered. Our study was also limited by the chronic implantation of the intraventricular cannula, which resulted in the development of a glial scar within the brain, and predisposed the TPP1-deficient mice (both enzyme-treated and mock-treated) to fatal seizures ~100-110 days of age (data not shown). Heterozygous mice receiving the implant were never observed to have seizures. Although it is interesting that TPP1-deficient mice are more susceptible to seizures than heterozygous littermates, this confounding factor precluded the use of survival as an outcome measure in our study. Similar studies in large animal models can be done with intrathecal cannulas that do not require passage through the brain parenchyma, thus minimizing the risk of seizures due to glial scar formation.
An important concern accompanying the administration of any exogenous protein to patients is the possibility of immune responses against the protein. In this study, TPP1-deficient mice appeared to tolerate the enzyme replacement well, with no immediately observable responses to enzyme delivery. Anti-TPP1 antibodies were generated in response to the enzyme (data not shown), but this is not unexpected given that enzyme replacement studies in Gaucher, Fabry, and mucopolysaccharidoses I, II, and VI all reported development of immunoglobulin G antibodies against the administered enzyme even when patients retained residual enzyme activity. In some cases these antibodies can neutralize the activity of the administered enzyme. 14, 15, 30, 31 However, tolerization regimens to overcome this limitation exist and continue to be developed and improved. Evidence from this and our prior work 34 suggests that the cerebrospinal fluid can be exploited for delivery and distribution of lysosomal enzymes. The results of the current study suggest that TPP1 can also be delivered via this route, and they warrant additional studies in large animal models. Interestingly, TPP1 activity can be detected in serum following infusion into the lateral ventricles, suggesting that central administration of TPP1 may also indirectly rescue enzyme activity in the periphery. Despite the apparently CNS-specific clinical symptoms in NCL, lysosomal storage is also observed in peripheral tissues, suggesting that peripheral enzyme replacement may be necessary if CNS disease is rescued or delayed.
MaterIals and Methods
Experimental animals. CLN2 -/-mice have been described previously, 7 and were backcrossed with C57BL/6 mice at the University of Iowa animal facility. All animal maintenance conditions and experimental protocols were approved by the University of Iowa Animal Care and Use Committee.
Human tissue specimens. Paraffin-embedded tissue samples were obtained from the archives of (i) Human Brain and Spinal Fluid Resource Center; (ii) NICHD Brain and Tissue Bank for Developmental Disorders; (iii) The MRC London Neurodegenerative Diseases Brain Bank, Institute of Psychiatry, King's College London. These specimens were obtained at routine autopsies of patients with a diagnosis of LINCL confirmed by mutational analysis, TPP1 enzyme assays or ultrastructural criteria (n = 4; mean age at death 11.5 years) or controls (n = 3; aged 2, 25, and 26 years) with informed written consent from their families. At autopsy, tissues were fixed immediately by immersion in 4% neutral-buffered formaldehyde, routinely embedded in paraffin wax, and then cut at 7 µm on a sledge microtome (Leica Microsystems, Welwyn Garden City, UK). Study protocols for the use of human material were approved by the Ethical Research Committees of the Institute of Psychiatry (approval numbers 223/00, 181/02).
Recombinant TPP1 expression and purification. Chinese hamster ovary cells expressing human TPP1 described previously 28 were seeded in 850-cm 2 roller bottles in 200 ml phenol red-free Dulbecco's modified Eagle's medium/F12 (Gibco, Carlsbad, CA, cat. no. 11039-021) containing 10% fetal bovine serum. Once confluent, the medium was changed to Dulbecco's modified Eagle's medium/F12 without fetal bovine serum. After 7 days of incubation, the conditioned medium was centrifuged to remove cells and sterile-filtered through a 0.2-µm filter.
The purification process was done as described previously, 28 with minor modifications. Conditioned medium was adjusted to 20 mmol/l Tris pH 8.0 and 2.4 mol/l NaCl, then refiltered. Seventy five column volumes (CVs) of the adjusted medium were loaded at 300 cm/hour on a Butyl Sepharose 4 FF column pre-equilibrated in 20 mmol/l Tris, 2.4 mol/l NaCl, pH 8.0. The column was washed with 3 CV 20 mmol/l Tris, 2.4 mol/l glycine, pH 8.0 and eluted with an 8 CV gradient of 2.4-0 mol/l glycine in 20 mmol/l Tris pH 8.0. Fractions containing TPP1 were pooled, adjusted to 40 mmol/l NaCl, then loaded at 300 cm/hour on a 12-ml UnoQ12 column pre-equilibrated in 20 mmol/l Tris, 40 mmol/l NaCl, pH 8.0. The column was then washed with 3 CV equilibration buffer and eluted by using an 11 CV gradient of 40-550 mmol/l NaCl in 20 mmol/l Tris pH 8.0. Fractions containing TPP1 were pooled for maximal purity and recovery. This pool was diluted with an equal volume of 20 mmol/l Tris, 40 mmol/l NaCl, pH 8.0 and applied to a Blue Sepharose column equilibrated in the same buffer. The unbound TPP1 was concentrated and buffer exchanged to phosphate-buffered saline pH 7.2 in a stirred cell using a 10,000 molecular weight cut-off membrane. The final purified TPP1 was sterile-filtered and stored frozen at -80 °C until use.
Surgical implantation of osmotic pumps. CLN2 -/-mice (60 days old) were anesthetized with ketamine (100-125 mg/kg) and xylazine (10-12.5 mg/ kg). Cannulas, (0.31-mm diameter, Brain Infusion Kit III; Alzet Cupertino, CA) were stereotaxically implanted into the lateral ventricles (A/P -0.4-mm caudal, M/L 1.0 mm, D/V -2.0 mm). The cannula was connected via a catheter tube to an osmotic pump (Model 1002, Alzet, Cupertino, CA), which was subcutaneously implanted in the left flank of each mouse. Each pump was filled with 100 µl purified TPP1 proenzyme (1 mg/ml). Pumps were excised at the end of the study to confirm delivery of the enzyme.
Quantitation of tremor in TPP1-deficient mice. Mean tremor amplitude was assessed with a tremor monitor (SD Instruments, San Diego, CA). Enzyme-treated CLN2 -/-mice, saline mock-treated CLN2 -/-mice, and age-matched CLN2 +/-control littermates (n = 5-11 per group) were each allowed a 1-minute habituation period on the testing platform, after which 20 samples of tremor amplitude were taken per mouse. Samples were taken every 5 seconds, and each sample consisted of the mean amplitude over a 1-second interval. Mice were assayed every 5 days beginning at 55 days of age until kill at 105 days of age. Statistical difference between groups at each timepoint was calculated by students t-test.
Mouse tissue processing and histology. Animals were deeply anesthetized with intraperitoneal ketamine (100-125 mg/kg) and xylazine (10-12.5 mg/kg), then transcardially perfused with normal saline (20 ml) followed by 4% paraformaldehyde in normal saline (20 ml). Brains were then extracted and postfixed in 4% paraformaldehyde for 24 hours at 4 °C. 40 µmol/l thick sections were cut on a freezing microtome and collected free floating in cryoprotectant solution (30% ethylene glycol, 15% sucrose, 0.05% sodium azide, in Trisbuffered saline) for storage at -20 °C. Immunohistochemistry was done with the following antibodies: mouse-anti-GFAP (Sigma, St. Louis, MO; 1:500), mouse anti-Neu-N (Chemicon, Temecula, CA; 1:100), mouse anti-calbindin D-28K (Sigma, St. Louis, MO; 1:3,000). All antibodies were diluted in Trisbuffered saline with 2% bovine serum albumin, 0.1% NaN 3 , and 0.05% Tween 20. After incubation with primary antibody overnight at 4 °C, tissue sections were rinsed with Tris-buffered saline and incubated with the appropriate secondary antibody:biotinylated goat anti-mouse (Jackson, Immuno Research, West Grove, PA; 1:5,000), Alexa 488-conjugated goat anti-rabbit (Invitrogen, Carlsbad, CA; 1:1,000). Stains were developed with 3,3′-diaminobenzidine peroxidase substrate kit (Vector Laboratories, Burlingame, CA).
Human tissue processing and histology. As described previously, paraffin wax sections of human tissue sections were stained to reveal the presence of GFAP immunoreactive astrocytes (polyclonal rabbit anti-GFAP, 1:10,000; Dako Glostrup, Denmark), and counterstained with hematoxylin to reveal neuronal cytoarchitecture. 27 Multichannel confocal microscopy (Leica SP5, Leica Microsystems, UK) was used to assess the distribution of autofluorescent storage material in tissue that had been immunofluorescently stained to reveal GFAP immunoreactive astrocytes (polyclonal rabbit anti-GFAP, followed by Alexa 488-labeled goat anti-rabbit immunoglobulin G, 1:500; Molecular Probes, Eugene, OR). A standard Bielschowsky silverstain method was used to assess axonal degeneration.
Thresholding analysis with Image J software. Digital images (×40 magnification) of immunostained brain sections were taken (Images from three sections per mouse per region of interest, n = 3 mice per group in Figure 1 , n = 5-9 mice per group in Figure 5 ). Once opened in Image J, images were converted to 8-bit grayscale images. The thresholding function was then used to set a black and white threshold corresponding to the immunostain. Once a threshold is set, the "Analyze Particles" function was used to sum up the total area of positive staining and calculate the fraction of the total area that is positive for the stain.
TPP1 enzyme activity assay in mouse brain homogenate. TPP1 activity was assayed via a modification of the method described previously. 29 Mice were transcardially perfused with ice-cold normal saline, and extracted www.moleculartherapy.org vol. 16 no. 4 april 2008 brains were cut into 10 coronal sections through both hemispheres using a brain matrix. Brain sections were homogenized with a laboratory homogenizer (P200; Pro Scientific, Oxford, CT) in 300 µl ice-cold homogenization buffer-0.1% Triton X-100 in normal saline, with complete protease inhibitor cocktail (Roche, Mannheim, Germany). Insoluble material was removed from the homogenate by centrifugation at 21 × 10 3 rcf at 4 °C × 15 minutes, and protein content in the supernatant was quantified by DC Protein Assay (Biorad, Hercules, CA). Protein (10 µg) was added to wells of a 96-well black wall plate containing 50 µl sodium citrate buffer (pH 4.0). The enzyme reaction was then initiated by addition of substrate (250 µmol/l Ala-AlaPhe 7-amido-4-methylcoumarin in sodium citrate buffer, pH 4.0). Plates were then read in a FLUOstar microplate reader (BMG Labtechnologies, Durham, NC) at 37 °C with a 460-nm emission filter.
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